Results 1 to 10 of about 655,135 (300)

Effectiveness of two doses of Euvichol-plus oral cholera vaccine in response to the 2017/2018 outbreak: a matched case–control study in Lusaka, Zambia [PDF]

BMJ Open, 2022
Introduction Zambia experienced a major cholera outbreak in 2017–2018, with more than 5905 cases reported countrywide, predominantly from the peri-urban slums of Lusaka city.
Victor M Mukonka, Modest Mulenga, C Michelo, Khozya Zyambo, Cephas Sialubanje, Muzala Kapina, Orbrie Chewe, Belem Blamwell Matapo, Albertina Moraes Ngomah, Brittany Gianetti, William Ngosa, Mpanga Kasonde, Kunda Musonda, Nyambe Sinyange, Patricia Bobo, Lucy Mazyanga, Nathan Bakyaita   +16 more
doaj   +3 more sources

Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study [PDF]

The Lancet Global Health, 2016
Background: Oral cholera vaccines represent a new effective tool to fight cholera and are licensed as two-dose regimens with 2–4 weeks between doses.
Dr. Andrew S Azman, PhD, Lucy A Parker, PhD, John Rumunu, MPH, Fisseha Tadesse, MPH, Francesco Grandesso, MPH, Lul L Deng, MD, Richard Laku Lino, MPH, Bior K Bior, PhD, Michael Lasuba, MS, Anne-Laure Page, PhD, Lameck Ontweka, BS, Augusto E Llosa, PhD, Sandra Cohuet, MD, Lorenzo Pezzoli, PhD, Dossou Vincent Sodjinou, MD, Abdinasir Abubakar, MD, Amanda K Debes, PhD, Allan M Mpairwe, MPH, Joseph F Wamala, MPH, Christine Jamet, MPH, Justin Lessler, PhD, Prof. David A Sack, MD, Marie-Laure Quilici, PhD, Iza Ciglenecki, MD, Francisco J Luquero, PhD   +24 more
doaj   +4 more sources

An overview of VaxchoraTM, a live attenuated oral cholera vaccine [PDF]

Human Vaccines & Immunotherapeutics, 2020
Cholera remains a public health threat among the least privileged populations and regions affected by conflicts and natural disasters. Together with Water, Sanitation and Hygiene practices, use of oral cholera vaccines (OCVs) is a key tool to prevent ...
Tarun Saluja, Vijayalaxmi V. Mogasale, Jean-Louis Excler, Jerome H. Kim, Vittal Mogasale   +4 more
doaj   +3 more sources

Urban cholera transmission hotspots and their implications for reactive vaccination: evidence from Bissau city, Guinea bissau. [PDF]

PLoS Neglected Tropical Diseases, 2012
BackgroundUse of cholera vaccines in response to epidemics (reactive vaccination) may provide an effective supplement to traditional control measures.
Andrew S Azman, Francisco J Luquero, Amabelia Rodrigues, Pedro Pablo Palma, Rebecca F Grais, Cunhate Na Banga, Bryan T Grenfell, Justin Lessler   +7 more
doaj   +15 more sources

Cholera Vaccines [PDF]

Journal of Travel Medicine, 2000
Cholera causes significant morbidity and mortality worldwide. For travelers, the risk of developing cholera per month of stay in a developing country is approximately 0.001%-0.01%, and cholera may present as traveler's diarrhea. In the United States, only a poorly tolerated, marginally effective, parenterally administered, phenol-inactivated vaccine is
Edward T. Ryan, Stephen B. Calderwood
openalex   +6 more sources

Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis [PDF]

The Lancet Global Health, 2015
Background: Between April and June, 2012, a reactive cholera vaccination campaign was done in Haiti with an oral inactivated bivalent whole-cell vaccine.
Dr. Louise C Ivers, MBBCh, Isabelle J Hilaire, MD, Jessica E Teng, MPH, Charles P Almazor, MD, J Gregory Jerome, MD, Ralph Ternier, MD, Jacques Boncy, MD, Josiane Buteau, MD, Prof. Megan B Murray, MD, Jason B Harris, MD, Molly F Franke, ScD   +10 more
doaj   +3 more sources

Overprescription of cholera vaccine. [PDF]

BMJ, 1990
P G Baddeley
  +12 more sources

Evaluation of oral cholera vaccine (Euvichol-Plus) effectiveness against Vibrio cholerae in Bangladesh: an interim analysis [PDF]

BMJ Global Health
Introduction Millions of Euvichol-Plus doses have been deployed from the global oral cholera vaccine stockpile in over 20 cholera-affected countries. However, information on Euvichol-Plus’s effectiveness is limited.
Amanda Tiffany, Ashraful Islam Khan, Firdausi Qadri, John D Clemens, Faisal Ahmmed, Farhana Khanam, Tahmina Shirin, Fahima Chowdhury, Md. Taufiqul Islam, Md Nazmul Islam, Md Nazmul Hasan Rajib, Md Ismail Hossen, Md. Taufiqur Rahman Bhuiyan, Shahinur Haque, Prasanta Kumar Biswas, Amirul Islam Bhuiyan, Zahid Hasan Khan, Mohammad Ashraful Amin, Aninda Rahman, S M Shahriar Rizvi, Lucy Breakwell   +20 more
doaj   +2 more sources

Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy. [PDF]

PLoS Neglected Tropical Diseases, 2012
Mass vaccinations are a main strategy in the deployment of oral cholera vaccines. Campaigns avoid giving vaccine to pregnant women because of the absence of safety data of the killed whole-cell oral cholera (rBS-WC) vaccine. Balancing this concern is the
Ramadhan Hashim, Ahmed M Khatib, Godwin Enwere, Jin Kyung Park, Rita Reyburn, Mohammad Ali, Na Yoon Chang, Deok Ryun Kim, Benedikt Ley, Kamala Thriemer, Anna Lena Lopez, John D Clemens, Jacqueline L Deen, Sunheang Shin, Christian Schaetti, Raymond Hutubessy, Maria Teresa Aguado, Marie Paule Kieny, David Sack, Stephen Obaro, Attiye J Shaame, Said M Ali, Abdul A Saleh, Lorenz von Seidlein, Mohamed S Jiddawi   +24 more
doaj   +3 more sources

Epidemiologic and Genomic Surveillance of Vibrio cholerae and Effectiveness of Single-Dose Oral Cholera Vaccine, Democratic Republic of the Congo [PDF]

Emerging Infectious Diseases
We conducted 4 years of epidemiologic and genomic surveillance of single-dose effectiveness of a killed whole-cell oral cholera vaccine (kOCV) and Vibrio cholerae transmission in the Democratic Republic of the Congo.
Christine Marie George, Alves Namunesha, Kelly Endres, Willy Felicien, Presence Sanvura, Jean-Claude Bisimwa, Jamie Perin, Justin Bengehya, Jean Claude Kulondwa, Ghislain Maheshe, Cirhuza Cikomola, Lucien Bisimwa, Alain Mwishingo, David A. Sack, Daryl Domman   +14 more
doaj   +2 more sources